BFM
MBX

Boothbay Fund Management’s MBX Biosciences MBX Stock Holding History

Boothbay Fund Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-72,800
Closed -$1.27M – 2456
2025
Q3 		$1.27M Buy
+72,800
New +$973K 0.02% 734

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Boothbay Fund Management's MBX Position: Q2 2026 in Review

Boothbay Fund Management reduced its MBX Biosciences (MBX) stake by 66% in Q2 2026, selling an estimated $4.81M and leaving 70,353 shares worth $3.88M. The position accounts for 0.05% of the portfolio, ranked #428.

Boothbay Fund Management first reported a position in MBX in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.21M in Q1 2026. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Boothbay Fund Management held 70,353 shares of MBX Biosciences worth $3.88M as of Q2 2026.
  • Boothbay Fund Management sold 137,696 MBX Biosciences shares in Q2 2026, an estimated $4.81M.
  • MBX Biosciences made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #428 holding.
  • Boothbay Fund Management first reported a position in MBX Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Boothbay Fund Management's MBX Biosciences position peaked at $6.21M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.